---
title: "TFI International Inc. Stock 12‑Month Price Target Raised to $171.44, Implies 18% Upside"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294109148.md"
description: "TFI International Inc.'s average 12-month price target was raised to $170.18 (implying ~17% upside) by 19 analysts, up from $165.44. The consensus rating remains 'Buy' across 22 covering analysts, with 15 Buys, 7 Holds, and 0 Sells. Price forecasts range from $120.19 to $195 per share."
datetime: "2026-07-28T20:20:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294109148.md)
  - [en](https://longbridge.com/en/news/294109148.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294109148.md)
generator: "portal-rs"
---

# TFI International Inc. Stock 12‑Month Price Target Raised to $171.44, Implies 18% Upside

-   According to estimates from 19 analysts, TFI International Inc. stock's average price target has risen from $165.44 to $170.18, with forecasts ranging from $120.19 to $195 per share
-   Based on the Jul. 27 closing price, the updated target implies approximately 17% potential upside
-   Consensus rating remains at “Buy” across 22 covering analysts, with 15 Buys, 7 Holds and 0 Sells

Explore more price target data and ratings for TFI International Inc. on the , and track all previous and future analyst recommendations for TFI International Inc. in the dedicated News Flow.

**Disclaimer**

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [TFII.US](https://longbridge.com/en/quote/TFII.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [Apnimed, Inc. reports Q2 results](https://longbridge.com/en/news/298366495.md)
- [Tecsys Inc. declares CAD 0.09 dividend](https://longbridge.com/en/news/298741855.md)
- [Braveheart Bio, Inc. reports Q2 results](https://longbridge.com/en/news/298361396.md)
- [Nektar Therapeutics (NKTR) Lands Lancet Backing, Is The Upside Already Priced In?](https://longbridge.com/en/news/298137481.md)
- [Does Toro (TTC) Prioritizing Productivity Gains Hint At A Deeper Shift In Its Profit Playbook?](https://longbridge.com/en/news/298119884.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**